Inhibikase Therapeutics Initiates Medical and Patient Awareness Campaign for its Phase 2 '201' Trial Evaluating IkT-148009 in Parkinson's Disease
- Company to highlight the 201 trial at multiple regional seminars for physicians - - Up to 61% of clinical sites actively screening patients by close of 2Q23 - BOSTON and ATLANTA, June 21, 2023... | June 21, 2023
Source: marketscreener.com